White Anne E.
Known title: SVP & Pres-Lilly NeuroscienceCIK: 0001752313
Associated companies
Transaction History
| LLY | ▲ Buy | Grant | 6,829 | $5.9M | 2/10/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,457 | $1.2M | 2/1/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,269 | $0 | 2/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 5,363 | $4.0M | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,124 | $0 | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,844 | $1.2M | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Open Market | 2,500 | $866K | 2/13/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 2,500 | $857K | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Grant | 8,562 | $3.0M | 2/10/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 3,252 | $1.1M | 2/1/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 7,264 | $0 | 2/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 11,348 | $2.8M | 2/9/2022 | View on chart |
| LLY | ▲ Buy | Option Exercise | 9,368 | $0 | 2/1/2022 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 4,204 | $1.0M | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Eli Lilly Gains EU Support for Weight‑Loss Pill, Eyes New Drug Pipeline
The European Medicines Agency has endorsed Eli Lilly’s weight‑loss medication, giving the company a regulatory green light in a major market. The approval could broaden the drug’s availability and strengthen Lilly’s position in the obesity treatment space. Analysts also note that Lilly is developing three newer therapies that may further lift its prospects. These developments add to the company’s growth narrative.
Eli Lilly Gains EU Support for Weight‑Loss Pill, Eyes New Drug Pipeline. The European Medicines Agency has endorsed Eli Lilly’s weight‑loss medication, giving the company a regulatory green light in a major market. The approval could broaden the drug’s availability and strengthen Lilly’s position in the obesity treatment space. Analysts also note that Lilly is developing three newer therapies that may further lift its prospects. These developments add to the company’s growth narrative.